New Obesity Drug Could Launch in U.S. Before 2015

Danish drug-maker Novo Nordisk says its anti-obesity treatment liraglutide could become available for sale in the U.S. by the end of 2014. More 

JCPenney Same-Store Sales Sink: 6 Stocks in 60 Seconds

This week's video: JCPenney's same-store sales fell 17% in Q1. Also, find out why Arena Pharmaceuticals and Toyota are both celebrating. More 

Dow 15000! — Tuesday’s IP Market Recap

The Dow Jones Industrial Average closed above the 15000 mark for the first time ever, and the S&P 500 continued its record-setting rally. More 

Belviq Is Not the Next Fen-Phen … Probably

Arena Pharmaceuticals' withdrawal of its European application for Belviq has turned the stock into a three-ring circus. Don't panic -- just get the facts straight. More 

Data Drives the Rally — Tuesday’s IP Market Recap

Investors got a double good-news whammy on the housing and manufacturing fronts, though homebuilders didn't join in the market's broad-based gains. More 

Late Stock Rally Pares Losses — Tuesday’s IP Market Recap

Continued concerns over Cyprus held stocks down most of the day, though a late rally cut back losses across the board and helped the Dow finish in the black. More 

Keryx: An Important Biotech Reality Check in 5, 4, 3 …

This stock's tripling in the past month is your prototypical biotech "win." But if you don't lock in your gains now, you don't understand the game. More